600750.SH
华润江中
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 22.52
−8.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.1B | 4.2B | 4.4B | 4.6B | 3.9B |
| Cost of Revenue | 1.4B | 1.5B | 1.6B | 1.6B | 1.4B |
| Gross Profit | 2.7B | 2.8B | 2.8B | 2.9B | 2.5B |
| Operating Expenses | |||||
| R&D Expense | 154.5M | 152.8M | 130.4M | 141.4M | 100.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 217.9M | 224.7M | 229.0M | 221.0M | 205.8M |
| Selling & Marketing Expense | 1.2B | 1.3B | 1.5B | 1.6B | 1.5B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.6B | 1.7B | 1.8B | 2.0B | 1.8B |
| Cost and Expenses | 3.0B | 3.1B | 3.5B | 3.6B | 3.2B |
| Operating Income (EBIT) | 1.2B | 1.2B | 1.0B | 912.8M | 748.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.2B | 1.2B | 1.0B | 916.1M | 753.3M |
| Income Tax Expense | 221.4M | 225.2M | 165.1M | 129.1M | 106.9M |
| Bottom Line | |||||
| Net Income | 909.8M | 906.7M | 788.2M | 718.7M | 598.2M |
| Earnings from Cont. Ops | 992.8M | 987.6M | 860.5M | 787.0M | 646.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 909.8M | 906.7M | 788.2M | 718.7M | 598.2M |
| Per Share | |||||
| Basic EPS | CN¥1.44 | CN¥1.43 | CN¥1.25 | CN¥1.14 | CN¥0.95 |
| Diluted EPS | CN¥1.44 | CN¥1.43 | CN¥1.25 | CN¥1.14 | CN¥0.95 |
| Revenue Per Share | CN¥6.50 | CN¥6.65 | CN¥7.03 | CN¥7.22 | CN¥6.17 |
| Shares | |||||
| Basic Shares Outstanding | 626.2M | 634.0M | 630.6M | 630.4M | 629.7M |
| Diluted Shares Outstanding | 626.2M | 634.0M | 630.6M | 630.4M | 629.7M |
| Profitability Metrics | |||||
| EBITDA | — | 1.3B | 1.2B | 1.0B | 868.9M |
| D&A | — | 150.9M | 136.2M | 124.8M | 120.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026